Advanced primary liver cancers (hepatocellular carcinoma (HCC), combined hepatocellular–cholangiocarcinoma (cHCC-CCA), cholangiocarcinoma (CCA), fibrolamellar carcinoma (FLC), hepatic sarcoma (HS), and epithelioid haemangioendothelioma (HEHE) remain difficult to treat after failure of first-line therapy. The 2025 French Genomic Medicine Initiative aimed to identify actionable targets for personalized treatment.
Journal of Hepatology published a clinical update in Research Highlights on 19 Mar 2026.
The item focuses on Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French Genomic Medicine Initiative.
Review the original article for the full source wording and details.